| Nov 9 |
Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer
|
| Nov 5 |
Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2024 Financial Results on November 12, 2024
|
| Oct 22 |
Corvus stock climbs 7% following Mizuho upgrade
|
| Oct 17 |
Insiders of Corvus Pharmaceuticals Getting Good Value On Their US$1.03m Investment
|
| Sep 30 |
Why Nio Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
|
| Sep 18 |
Casella Waste Systems, SES AI And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
|
| Sep 11 |
Corvus Stock Up on Initiation of Phase III Lymphoma Study on Lead Drug
|
| Sep 10 |
Corvus spikes as late-stage trial for lead asset announced
|
| Sep 10 |
Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma
|
| Sep 3 |
Corvus Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
|
